The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Molecular mechanisms underlying deregulation of C/EBP alpha in acute myeloid leukemia

Author

Summary, in English

The CEBPA gene encodes a transcription factor protein that is crucial for granulocytic differentiation, regulation of myeloid gene expression and growth arrest. Mutations in one or both alleles of CEBPA are observed in about 10% of patients with acute myeloid leukemia (AML). Moreover, other genetic events associated with AML have been identified to deregulate C/EBP alpha expression and function at various levels. Recently developed mouse models that accurately mimic the genetic C/EBP alpha alterations in human AML demonstrate C/EBP alpha's gatekeeper function in the control of self-renewal and lineage commitment of hematopoietic stem cells (HSCs). Moreover, these studies indicate that CEBPA mutations affect HSCs in early leukemia development by inducing proliferation and limiting their lineage potential. However, the exact relationship between 'pre-leukemic' HCSs and those cells that finally initiate leukemia (leukemia-initiating cells) with disturbed differentiation and aberrant proliferation remains elusive. More research is needed to identify and characterize these functionally distinct populations and the exact role of the different genetic alterations in the process of leukemia initiation and maintenance.

Department/s

Publishing year

2010

Language

English

Pages

557-568

Publication/Series

International Journal of Hematology

Volume

91

Issue

4

Document type

Journal article review

Publisher

Springer

Topic

  • Cell and Molecular Biology

Keywords

  • differentiation
  • Myeloid
  • C/EBP alpha
  • Transcription factor
  • AML
  • Leukemia
  • Bi-allelic mutation

Status

Published

ISBN/ISSN/Other

  • ISSN: 0925-5710